F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research summarized by The Journal of Nuclear Medicine. The comprehensive literature review of molecular imaging findings sheds light on how COVID-19 affects the brain and identifies important implications for other neurological conditions, like Parkinson’s disease or Alzheimer’s disease.

Neurological symptoms are present in roughly two-thirds of hospitalized COVID-19 patients. Symptoms include fatigue, loss of smell, attention problems and memory loss. Patients who have more severe COVID-19 cases, are older, or have pre-existing conditions are more likely to experience these neurological issues.

Molecular imaging with PET or SPECT has been used to determine how COVID-19 affects the brain; however, these scans often show conflicting results. To make sense of the data, researchers conducted a comprehensive, systematic and critical review of molecular imaging studies in neuropsychiatric COVID-19 cases.

Their report was structured according to neurological symptoms and how they developed over time. The five symptoms included in the report were encephalitis, Parkinsonism and other neurodegenerative diseases, focal symptoms/lesions, encephalopathy, and post-COVID-19 syndrome. This helped the researchers to understand potential underlying (and most likely diverse) causes of the symptoms and to unravel discrepancies in the PET and SPECT literature.

“The presented studies are of high importance for patients struggling with neurological or cognitive aftermaths of COVID-19,” said Philipp T. Meyer, MD, PhD, head of the Department of Nuclear Medicine of the Medical Center–University of Freiburg, in Freiburg, Germany. “To the best of our knowledge there are no convincing studies clearly demonstrating relevant and irreversible brain damage, except for disease complications like brain infarcts and bleedings. Thus, from our perspective, in the vast majority of cases there is no reason to assume that reported impairments will be permanent and not responsive to treatment.”

What are the implications of this research for the future of molecular imaging of COVID-19 neurological symptoms? First, there is a clear need for further well-designed studies. “These need to be prospective, recruit larger patient cohorts, follow accepted syndrome or stage definitions, and use proper methodology,” noted Jonas A. Hosp, MD, attending physician of the Department of Neurology and Clinical Neuroscience of the Medical Center–University of Freiburg, in Freiburg, Germany. “Carefully designed studies of COVID-19 populations will be of great interest moving forward.”

Second, there are several potential clinical applications of molecular imaging in COVID-19 patients with cognitive or neurological impairment. “It may be the case that COVID-19 unmasked or hastened a pre-existing neurodegenerative disease like Parkinson’s or Alzheimer’s,” said Meyer. “Molecular imaging could be used to identify these patients.”

For more information: www.snmmi.org

Related COVID Content:

COVID-19 Fallout May Lead to More Cancer Deaths

Kawasaki-like Inflammatory Disease Affects Children With COVID-19

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine

Case Study Describes One of the First U.S. Cases of MIS-C

NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19

Related Content

News | Proton Therapy

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology ...

Time July 01, 2022
arrow
News | Radiology Business

June 29, 2022 — Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed ...

Time June 29, 2022
arrow
News | Contrast Media

June 23, 2022 — Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol ...

Time June 23, 2022
arrow
News | SNMMI

June 22, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear ...

Time June 22, 2022
arrow
News | SNMMI

June 22, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13 ...

Time June 22, 2022
arrow
News | PET Imaging

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as ...

Time June 21, 2022
arrow
News | Radiology Imaging

June 21, 2022 — After less than two years of data collection and processing, the Radiological Society of North America ...

Time June 21, 2022
arrow
News | SNMMI

June 21, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the ...

Time June 20, 2022
arrow
News | SNMMI

June 16, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at ...

Time June 16, 2022
arrow
News | SPECT Imaging

June 15, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems ...

Time June 15, 2022
arrow
Subscribe Now